What Happened?
Shares of life sciences company Azenta (NASDAQ:AZTA) fell 9.1% in the afternoon session after the company announced, in a regulatory filing, that President and CEO John Marotta resigned from his executive roles and board seat, with current director Dr. Martin Madaus appointed as interim President and CEO.
Dr. Madaus, who joined the board in 2024 and serves as a Senior Operating Executive at the Carlyle Group, brings extensive executive experience from previous leadership roles at Millipore Corporation, Ortho-Clinical Diagnostics, and Roche Diagnostics North America. Azenta confirmed that executive search firm Heidrick & Struggles has been retained to identify a permanent successor. In addition to the management change, the company reaffirmed its fourth-quarter fiscal 2026 revenue guidance but noted that fourth-quarter adjusted EBITDA will be reduced by a one-time consulting expense of approximately $3 million.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Azenta? Access our full analysis report here, it's free .
What Is The Market Telling Us
Azenta's shares are extremely volatile and have had 30 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 7 months ago when the stock dropped 24.6% on the news that it reported mixed fourth-quarter results that failed to impress investors. While the company's revenue of $148.6 million was flat year over year, it did narrowly beat Wall Street's estimates. Similarly, its adjusted earnings per share of $0.14 met expectations. However, the positive notes were overshadowed by a significant miss on profitability. Azenta's adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), a key measure of operational profitability, was $12.7 million, falling 29% short of the consensus forecast. The company's cash generation also weakened, with its free cash flow margin declining to 9.9% from 14.9% in the same quarter last year. Overall, the stagnant sales growth and considerable weakness in underlying profitability signaled to investors that the company's financial health was not as strong as hoped, leading to a sharp sell-off.
Azenta is up 1.5% since the beginning of the year, but at $33.89 per share, it is still trading 17.4% below its 52-week high of $41.01 from January 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Azenta's shares 5 years ago would now be looking at only $414.94.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal.Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you're unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE .
